Evidence map›Paper›PMID 36009984›Full record

ArticleAntibiotics (Basel, Switzerland)2022

Development of Dicationic Bisguanidine-Arylfuran Derivatives as Potent Agents against Gram-Negative Bacteria.

Catarina Bourgard, Diego Rodríguez-Hernández, Anastasia Rudenko, Carolin Rutgersson, Martin Palm, D G Joakim Larsson, Anne Farewell, Morten Grøtli, Per Sunnerhagen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Catarina BourgardDepartment of Chemistry and Molecular Biology, University of Gothenburg, S-405 30 Gothenburg, Sweden.ORCID 0000-0003-3469-703X
Diego Rodríguez-HernándezDepartment of Chemistry and Molecular Biology, University of Gothenburg, S-405 30 Gothenburg, Sweden.ORCID 0000-0002-1125-2399
Anastasia RudenkoDepartment of Chemistry and Molecular Biology, University of Gothenburg, S-405 30 Gothenburg, Sweden.ORCID 0000-0002-8868-1204
Carolin RutgerssonCentre for Antibiotic Resistance Research (CARe), University of Gothenburg, S-405 30 Gothenburg, Sweden.
Martin PalmDepartment of Chemistry and Molecular Biology, University of Gothenburg, S-405 30 Gothenburg, Sweden.ORCID 0000-0001-6509-507X
D G Joakim LarssonCentre for Antibiotic Resistance Research (CARe), University of Gothenburg, S-405 30 Gothenburg, Sweden.ORCID 0000-0002-5496-0328
Anne FarewellDepartment of Chemistry and Molecular Biology, University of Gothenburg, S-405 30 Gothenburg, Sweden.ORCID 0000-0002-0841-4908
Morten GrøtliDepartment of Chemistry and Molecular Biology, University of Gothenburg, S-405 30 Gothenburg, Sweden.ORCID 0000-0003-3621-4222
Per SunnerhagenDepartment of Chemistry and Molecular Biology, University of Gothenburg, S-405 30 Gothenburg, Sweden.ORCID 0000-0002-0967-8729
University of Gothenburg · SE

Funding

Centre for Antibiotic Resistance Research (CARe) at University of Gothenburg N/ACoordenação de Aperfeicoamento de Pessoal de Nível Superior STINT-PROJ-20181009558PSven and Lilly Lawski Foundation N/A
6 · The paper itself

Abstract

Antibiotic resistance among bacteria is a growing global challenge. A major reason for this is the limited progress in developing new classes of antibiotics active against Gram-negative bacteria. Here, we investigate the antibacterial activity of a dicationic bisguanidine-arylfuran, originally developed as an antitrypanosomal agent, and new derivatives thereof. The compounds showed good activity (EC

Indexed as

antibiotic resistanceantimicrobial activitydicationic compoundsEscherichia coliESKAPE bacteriasensitivity profiling

Identifiers

PMID36009984
PMCPMC9404985
OpenAlexW4292261948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.